Intermediate-risk prostate cancer treated by permanent 125-iodine implants: 13 years of follow-up

Detalle

A. García Blanco, J. Anchuelo, M. Ferri A. Kannemman, J. Cardenal, J. Sanchez, P. Prada. Intermediate-risk prostate cancer treated by permanent 125-iodine implants: 13 years of follow-up. Comunicación oral. XVIII Congreso Nacional de Oncología Radioterápica (SEOR). Valencia, Junio 2015.